Technology Overview

A novel implantable biomedical material requires no chemical crosslinking agents. It maintains a liquid form at room or low temperatures and undergoes rapid gelation when exposed to body temperature. The material is highly biocompatible and biodegradable.

In its liquid state, it can be injected into the affected area. Once delivered, it instantly transitions into a gel that conforms precisely to the geometry of the damaged tissue, creating a stable protective layer and filling voids. It is designed to serve as a sustained-release carrier for antibiotics, drugs, growth factors, or cells, ensuring extended retention at the target site (up to 30 days), thereby enhancing therapeutic efficacy and reducing the frequency of administration.

Development milestones achieved include GMP pilot-scale production, preclinical safety and efficacy validation, and QMS product certification.

Technical Superiority

1. Minimally invasive surgical alternative: Injectable liquid form enables treatment via syringe instead of open surgery, lowering both surgical frequency and risk.

2. Rapid gelation and adaptability: Transforms into a gel upon injection and conforms precisely to tissue, providing long-lasting protection and therapeutic effect.

3. Biocompatible and absorbable: Minimizes foreign body reactions and reduces the need for secondary interventions.

4. Crosslinker-free for safety: Eliminates the need for chemical crosslinking agents, reducing concerns of chemical residues.

5. Addresses limitations of similar materials: Improves stability and reduces acidification during degradation, with an expanded gelation temperature range to avoid adverse reactions during fever.

Application

1. Anti-adhesion barrier and drug delivery post-complex surgery.

2. Degenerative and Associated Arthritis Treatment

3. Fracture and Bone Defect Treatment